




公告日期	2026/8/5
異動類別	藥品變更
異動原因	製造廠變更
異動描述	Epirubicin inj 10mg/5mL/vial (Pharmorubicin®)泛艾黴素靜脈注射劑廠商來文，自批號FR12501C起，製造廠/產地由「Pfizer (Perth) Pty Ltd/ Australia」變更為「Zydus Hospira Oncology Private Limited/ India」，外盒新增電子仿單二維條碼，藥廠logo、瓶身標籤、瓶器、仿單及國際條碼變更，藥品包裝變更。 舊品用罄，啟用新品。

異動內容		
	舊藥品	新藥品
料號	305051	
學名	Epirubicin	
商品名	Pharmorubicin	
中文名	泛艾黴素靜脈注射劑	
主成份及含量	10mg/5mL/vial	
製造廠名稱	Pfizer (Perth) Pty Ltd (輝瑞)	
產地	澳大利亞	
健保代碼	BC22695221	
外觀/圖檔		
用法	靜脈滴注	
小孩劑量	Safety and efficacy have not been established in pediatric patients.	

成人劑量	Breast cancer, adjuvant treatment, IV: Usual dose: 60 mg/m2 on days 1 and 8 every 28 days for 6 cycles in combination with cyclophosphamide and fluorouracil (CEF-120 regimen, should also receive prophylactic antibiotic therapy with sulfamethoxazole/trimethoprim or fluoroquinolone) or 100 mg/m2 on day 1 every 21 days for 6 cycles in combination with cyclophosphamide and fluorouracil (FEC-100 regimen) Lifetime maximum dose: 900 mg/m2 Risk of congestive heart failure increases rapidly above total cumulative doses of 900 mg/m2
副作用	